Overview

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This research is being done to study a combination of Brentuximab vedotin and Rituximab for the treatment of relapsed Hodgkin's Lymphoma (HL).
Phase:
Phase 0
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Treatments:
Antibodies, Monoclonal
Rituximab